A Clinical Study of Faropenem on Treatment of Acute Bacterial Infections
10.3969/j.issn.0253-9896.2009.10.011
- VernacularTitle:法罗培南钠片剂治疗急性细菌感染的临床研究
- Author:
Ping HE
;
Demeng LIU
;
Shiduo SONG
;
Liying CUI
;
Yaping MENG
;
Tianduo CHEN
;
Ganping ZHONG
;
Shuwen YANG
- Publication Type:Journal Article
- Keywords:
cefaclor;
anti-bacterial agents;
bacterial infections;
multicenter study;
treatment outcome
- From:
Tianjin Medical Journal
2009;37(10):849-852
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the clinical efficacy and safety of domestic faropenem in the treatment of acute bacterial infections. Methods: A multicenter, randomized, double blind and double simulation clinical study was conducted to compare the efficacy and safety of faropenem and cefaclor in the treatment of acute bacterial infection. Patients in trial group(n = 122) were given faropenem 250 mg，and in control group (n = 118) were given cefaclor 200 mg，3 times daily for 7 to 10 days.Results: The clinical cure rates were 33.61% and 27.12% in trail and control groups respectively and the clinical effective rates were 87.70% and 83.05% respectively. There was no significant difference in terms of clinical effectiveness between the two groups（P > 0.05）. The adverse reaction rates were 7.32% in trial group and 3.36% in control group（P > 0.05）. The adverse reaction of the trial group was mainly exaltation of aminotransferase, which did not affect the therapy. No severe adverse reaction was found.Conclusion: Domestic faropenem is effective and safe for the treatment of bacterial respiratory tract and urinary tract infections.
